Head-To-Head Review: Orgenesis (NASDAQ:ORGS) versus BridgeBio Pharma (NASDAQ:BBIO)

Orgenesis (NASDAQ:ORGS) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Orgenesis and BridgeBio Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0	0	0	0	0.00
BridgeBio Pharma	0	2	12	0	2.86

BridgeBio Pharma has a consensus price target of $47.69, indicating a potential upside of 73.49%. Given BridgeBio Pharma’s stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Orgenesis.

Profitability

This table compares Orgenesis and BridgeBio Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
BridgeBio Pharma	-201.53%	N/A	-74.34%

Valuation & Earnings

This table compares Orgenesis and BridgeBio Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662,000.00	7.39	-$55.36 million	N/A	N/A
BridgeBio Pharma	$217.77 million	23.86	-$643.20 million	($2.41)	-11.41

Orgenesis has higher earnings, but lower revenue than BridgeBio Pharma.

Insider and Institutional Ownership

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 5.7% of Orgenesis shares are held by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Orgenesis has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Summary

BridgeBio Pharma beats Orgenesis on 9 of the 11 factors compared between the two stocks.

About Orgenesis

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

About BridgeBio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.